Press release 28 Jan 2008
Lpath Successfully Humanizes Breakthrough Anti-LPA Antibody,
Lpathomab(TM)
SAN DIEGO, CA, Jan 28, 2008
(MARKET WIRE via COMTEX News Network) -- Lpath, Inc. (OTCBB: LPTN), the
category leader in therapeutic agents against bioactive lipids, has
successfully humanized its Lpathomab(TM) monoclonal antibody against
lysophospholipid acid (LPA). As a promoter of tumorigenesis and
metastasis, LPA is an important bioactive lipid and a well-validated
cancer drug target. LPA is also a well-known contributor to neuropathic
pain.
The humanization of Lpathomab was a collaborative effort with DaTaMabs
LLP, an antibody engineering consultancy that provides an antibody
humanization design service using well-established CDR-grafting
methodology (www.DaTaMabs.com).
Press release: 20 Dec 2007
Anti-Bioactive-Lipid Category Leader, Lpath, Achieving Key 2007 Milestones
Press release: 04 Sept 2007
Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
SAN DIEGO, Sept. 4 /PRNewswire-FirstCall/ -- Lpath, Inc. (OTC Bulletin Board: LPTN), the category leader in therapeutic agents against bioactive lipids, reported positive results in several murine models of human cancer and AMD with Lpathomab(TM), the company's mouse monoclonal antibody against LPA (lysophosphatidic acid). These results confirm the expected potent anti-angiogenic and anti-metastatic actions of Lpathomab. Lpathomab was created using Lpath's proprietary ImmuneY2(TM) platform technology.
Based on this positive outcome, Lpath will collaborate with DaTaMabs of London, England, to humanize Lpathomab to create a lead antibody for pre- clinical development....
"Humanizing our Lpathomab antibody is a vital next step in moving the project into the clinic," said Genevieve Hansen, Ph.D., Lpath's vice president of research. "We've had great success in the past working with DaTaMabs and look forward to working with them again on our Lpathomab project."
